Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D001402:B-Lymphocytes / Q000276:immunology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000276:immunology / Q000628:therapy* / Q000821:virology; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D008727:Methotrexate